Skip to main content

Table 7 Univariate analysis of potential DDIs

From: A comprehensive evaluation of potentially significant drug-drug, drug-herb, and drug-food interactions among cancer patients receiving anticancer drugs

Characteristic

Frequency (%)

No. of DDIs

Median [Q1-Q3]

P-value

Age

  

 < 0.001 a

  ≤ 50

127(38.8%)

3.0 (1.0–5.0)

 

  > 50

200 (61.2%)

4.0 (2.0–8.0)

 

Gender

  

0.792 a

 Male

103(31.5%)

3.0 (2.0–7.0)

 

 Female

224 (68.5%)

3.0 (1.0–7.0)

 

BMI

  

0.242 b

  < 18.5

7 (2.1%)

2.0 (2.0–4.0)

 

 18.5–24.9

83 (25.4%)

3.0 (1.0–6.0)

 

 25–29.9

119 (36.4%)

4.0 (2.0–7.0)

 

  ≥ 30

118 (36.1%)

4.0 (2.0–7.0)

 

Cancer type

  

0.389 a

 Hematological

83 (25.4%)

3.0 (2.0–5.0)

 

 Solid

244 (74.6%)

4.0 (1.0–7.0)

 

Metastasis

  

0.304 a

 No

195 (59.6%)

4.0 (2.0–7.0)

 

 Yes

132 (40.4%)

3.0 (1.0–7.0)

 

Palliative

  

0.106 a

 No

200 (61.2%)

4.0(2.0–7.0)

 

 Yes

127 (38.8%)

3.0 (1.0–6.0)

 

Duration of treatment

  

0.001 b

  < 1

193 (59.0%)

4.0 (2.0–7.0)

 

 1–3

90 (27.5%)

3.0 (1.0–6.0)

 

  > 3

44(13.5%)

2.0 (1.0–4.8)

 

Number of comorbid diseases

  

 < 0.001 b

 0

165 (50.5)

1.0 (1.0–2.0)

 

 1

91 (27.8)

2.0 (1.0–4.0)

 

  ≥ 2

71 (21.7)

4.0 (3.0–4.0)

 

All drugs used

  

 < 0.001 a

  ≤ 7

158 (48.3%)

2.0 (1.0–3.0)

 

  > 7

169(51.7%)

5.0 (3.0–10.0)

 

Anticancer treatment

  

0.001 a

  ≤ 2

200 (61.2%)

3.0 (1.0–5.8)

 

  > 2

127 (38.8%)

5.0 (2.0–8.0)

 

Education

  

0.314 b

 Not educated

18 (5.5%)

6.0 (2.5–9.0)

 

 Standard < 5

32 (9.8%)

3.0 (0.0–7.0)

 

 Standard 5–10

105(32.1%)

3.0 (2.0–6.5)

 

 Standard 11–12

100 (30.6%)

3.0 (1.0–7.0)

 

 University qualification

72 (22.0%)

3.0 (1.0–6.0)

 
  1. aThe statistical significance of differences was calculated using the Mann–Whitney U test
  2. bThe statistical significance of the differences was calculated using the Kruskal–Wallis test
  3. The bold P-value indicates significant differences